Evidence-based goals in LDL-C reduction

Area of Science:

• Cardiology
• Pharmacology
• Preventive Medicine

Background:

• Cardiovascular disease (CVD) event reduction with statin therapy correlates with the magnitude of low-density lipoprotein cholesterol (LDL-C) lowering.
• Epidemiological and genetic studies support a graded, cardio-protective effect of lifelong low atherogenic cholesterol exposure.
• Current LDL-C treatment targets may not represent a threshold for benefit, suggesting potential advantages for further LDL-C reduction.

Purpose of the Study:

• To review safety and efficacy data of therapies providing LDL-C lowering beyond statin therapy.
• To evaluate the implications of intensive LDL-C lowering for current guideline targets.
• To discuss the role of pre-treatment LDL-C levels and statin therapy in CVD event prevention.

Main Methods:

• Review of recent safety and efficacy data from clinical trials of adjunctive LDL-C lowering therapies.
• Analysis of epidemiological and genetic studies on cholesterol exposure and cardiovascular risk.
• Discussion of current treatment guidelines in the context of pre-treatment LDL-C concentrations.

Main Results:

• Evidence suggests a continuous relationship between LDL-C reduction and CVD event reduction, without a discernible threshold.
• The number of patients needing treatment to prevent a CVD event varies significantly based on pre-treatment LDL-C levels.
• Patients with the highest LDL-C levels, even on maximal statin and ezetimibe therapy, achieve the greatest benefit from PCSK9 inhibitors.

Conclusions:

• Intensive LDL-C lowering, particularly with advanced therapies like PCSK9 monoclonal antibodies, offers substantial CVD risk reduction.
• Pre-treatment LDL-C concentration is a critical factor in determining the absolute benefit of LDL-C lowering therapies.
• Current treatment guidelines may need to consider more aggressive LDL-C lowering strategies for certain patient populations.